Skip to main content
Caplight Logo









Curesponse

Curesponse

Private
IsraelHealthcare & Life Scienceshttps://www.curesponse.com/

Last Round

Series B

Nov 15, 2021

Total Funding Raised

$14M

Company Overview

Curesponse is a biotechnology company that has developed a cancer treatment testing platform designed to identify effective therapy for individual patients.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Medical AI, Drug Discovery, Clinical Trials, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

cancer treatment predictionprecision oncologyfunctional precision medicineex vivo drug testingtumor microenvironmentTMEtumor organoidspatient-derived explantschemosensitivity testingAI in oncologycompanion diagnosticsCDxoncology decision supportdrug discovery servicessolid tumor testingclinical trial services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Curesponse Comparables

Compare Curesponse with similar companies based on industry and business-model similarity.

Curesponse comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
First Ascent Biomedical
87%
SageMedic Corp.
87%
Xilis
82%

Curesponse Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 15, 2021
Series AJun 5, 2020

Key People

Founding team and executive leadership

Seth Salpeter

Co-Founder & CTO

Founding Team

Curesponse Investors

Notable investors and investment history

Curesponse investors
InvestorRounds
aMoonSeries A
NCLSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 38% MoM, reaching 962.

  • Jun 5, 2025

    Grew 20% QoQ from 15 to 18 employees.

Curesponse Filings

Explore SEC and related filing metadata, where available.

Curesponse filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Curesponse's valuation, stock price, and market status.

Is Curesponse a public or private company?

Curesponse is a private company.

What is the current stock price of Curesponse?

Curesponse is a private company with no public stock price. No recent secondary market data is available.

How much is Curesponse worth (valuation)?

Valuation information for Curesponse is not publicly available.

Can I buy Curesponse stock?

Curesponse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Curesponse's last funding round?

Funding round information for Curesponse is not publicly available.

Who are the main investors in Curesponse?

Investor information for Curesponse is not publicly disclosed.

Will Curesponse IPO soon?

No public IPO plans have been announced for Curesponse.

How can I track Curesponse secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Curesponse's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIsrael
Employee Range11
Year Founded2017
Last FundingNov 15, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?